Access review01
Best GLP-1 providers, with the product question kept in view
A six-option access review that separates the care company, medicine and purchase agreement.
Read the explainer ↗Mechanism02
What “dual incretin” means—and what it leaves unanswered
Two receptor targets describe how a medicine acts. They do not give a patient a treatment ranking.
Read the explainer ↗Study reading03
How to read a head-to-head tirzepatide study
A result becomes more useful when the population, comparator and limits travel with it.
Read the explainer ↗Product identity04
Ingredient, brand and preparation: three labels to keep separate
A familiar ingredient name cannot do all the work of identifying the medicine in an offer.
Read the explainer ↗